TD Cowen Issues Positive Forecast for Thermo Fisher Scientific (NYSE:TMO) Stock Price

Key Points

• TD Cowen raised Thermo Fisher Scientific’s price target from $760 to $810 and maintained a “buy” rating, implying 18.21% upside from the prior close. The broader analyst consensus is “Moderate Buy,” with an average target of $672.67.
• Thermo Fisher reported stronger-than-expected quarterly results, with revenue rising 9.1% year over year to $12.14 billion and EPS of $6.68 versus the $6.40 consensus estimate. Analysts expect the company to generate $25.13 in full-year EPS.
• Despite the positive outlook, shares fell 1.3% to $685.20, while insiders sold $44.1 million of stock over the past 90 days. Institutional investors continue to hold a significant 89.23% stake in the company.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) had its price target raised by stock analysts at TD Cowen from $760.00 to $810.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a "buy" rating on the medical research company's stock. TD Cowen's price target indicates a potential upside of 18.21% from the company's previous close.

A number of other brokerages also recently weighed in on TMO. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday, October 3rd. Scotiabank started coverage on Thermo Fisher Scientific in a research report on Wednesday, September 9th. They issued an "outperform" rating on the stock. Stifel Nicolaus upped their price objective on Thermo Fisher Scientific from $650.00 to $775.00 and gave the company a "buy" rating in a research note on Thursday. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research report on Monday, July 6th. Finally, Barclays set a $775.00 target price on Thermo Fisher Scientific in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average target price of $672.67.

Thermo Fisher Scientific Stock Down 1.3%

Shares of TMO stock traded down $8.82 on Thursday, hitting $685.20. The stock had a trading volume of 663,180 shares, compared to its average volume of 2,262,024. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The business has a 50 day moving average of $642.42 and a 200 day moving average of $552.67. Thermo Fisher Scientific has a 12-month low of $435.27 and a 12-month high of $705.78. The stock has a market cap of $253.35 billion, a price-to-earnings ratio of 36.76, a price-to-earnings-growth ratio of 2.87 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, topping the consensus estimate of $6.40 by $0.28. The business had revenue of $12.14 billion for the quarter, compared to analysts' expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm's revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the previous year, the company earned $5.79 earnings per share. As a group, analysts expect that Thermo Fisher Scientific will post 25.13 EPS for the current year.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 275 shares of the company's stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $77,707,171.25. This represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 73,768 shares of company stock worth $44,122,820. Insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

A number of hedge funds and other institutional investors have recently bought and sold shares of TMO. Polaris Financial Partners bought a new position in shares of Thermo Fisher Scientific in the third quarter worth $32,000. Kilter Group LLC bought a new stake in Thermo Fisher Scientific during the second quarter valued at $25,000. Legacy Wealth Managment LLC ID grew its position in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after buying an additional 22 shares in the last quarter. Allied Private Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $26,000. Finally, MBM Wealth Consultants LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $29,000. Institutional investors own 89.23% of the company's stock.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Quarterly results exceeded expectations: Q3 revenue rose 9.1% year over year to $12.14 billion, while adjusted EPS increased 15% to $6.68, beating consensus estimates of $11.95 billion and $6.40, respectively. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Growth broadened across key end markets: Organic revenue growth reached 6%, supported by pharmaceutical demand, clinical research, bioproduction and electron microscopy. Management also highlighted continued customer activity, AI integration and signs of recovery in previously weaker markets. TMO Q3 deep dive
• Positive Sentiment: Profitability and outlook improved: Operating margin reached 24.5%, aided by portfolio actions and productivity initiatives. Thermo Fisher raised its full-year 2026 revenue and earnings outlook, including a 4% organic revenue-growth target. Three key takeaways
• Positive Sentiment: Analyst confidence increased: Robert W. Baird raised its price target from $723 to $756 and upgraded or reaffirmed an “outperform” rating, implying additional upside from the current trading level.
• Neutral Sentiment: Investors delivered a measured response: Despite the earnings beat and higher guidance, the stock’s reaction has been relatively restrained, suggesting that strong results may have been partly anticipated and that valuation remains an important consideration. Q3 earnings disconnect
• Negative Sentiment: Short-term caution remains: Early trading included selling pressure following the report, and put-option purchases rose about 52% above average volume, indicating that some investors are hedging against volatility or disappointment after the earnings release.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.